Schering-Plough’s temozolomide
Executive Summary
Oral cytotoxic agent has a 43% response rate in patients with gliomas previously untreated with chemotherapy, a Phase II study presented at ASCO May 18 finds. A total of 44 patients were treated with the drug, which was "well tolerated with little subjective toxicity and predictable myelosuppression," the study abstract states. The trial was led by investigators at Charing Cross Hospital in London. Schering-Plough plans to conduct further research on the compound.